mar ket w ith Net Sales of INR 94.6bn w ith 230 brands. R&D; - 7.5% of Sales. Chronic, semi-chronic therapies account for 54%. FY07 - FY 12: Sales CA GR - 27%, PA T CA GR - 25%. Vertically integrated w ith strengths in manufacturing and IP based products.12 Mfg sites of w hich 2 in Japan. A PI sites -5, For mulation sites -7. 5 FDA inspected sites. Exports account for 70% of sales w ith US-38%, ROW-17%, Japan-12%, Europe-3% . For mulations- 90% of sales and A PI -10%. In US Generics account for 78%, branded for mulations-22%. Plans 120 launches in 3-4 y rs - addressable market...